Botanical species · safety record

Hemidesmus indicus

The EFSA Compendium of Botanicals holds 7 constituent measurements, 1 adverse-effect record and 1 genotoxicity assay for Hemidesmus indicus. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Hemidesmus indicus (L.) R. Br. ex Schult.

7Constituent measurements
2Safety records
4Cited sources
35Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 35 licensed products naming Hemidesmus indicus as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Aged bark
  • Root
  • Root extract

What the records describe

Constituents measured

  • Alkaloids3
  • Saponins2
  • Coumarins1
  • Pregnane derivatives1

Plant parts

  • Roots and other underground parts5
  • Stem3
  • stalk3

Preparations

  • Solvent extraction6

Effect types

  • Hepatotoxicity1

Target tissues

  • Liver1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
CoumarinsRoots and other underground partsSolvent extractionPhytochemical screeningResolve DOI
Pregnane derivativesStem / stalkSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
AlkaloidsRoots and other underground partsSolvent extraction≥ 0.35 Microgram/gramPhytochemical screeningNo resolvable identifier
AlkaloidsRoots and other underground partsSolvent extraction≤ 0.75 Microgram/gramPhytochemical screeningNo resolvable identifier
AlkaloidsStem / stalkColorimetry, Spectroscopy (Spectrometry) and PhotometryNo resolvable identifier
SaponinsRoots and other underground partsSolvent extraction≥ 2.82 Microgram/gramPhytochemical screeningNo resolvable identifier
SaponinsRoots and other underground partsSolvent extraction≤ 3.2 Microgram/gramPhytochemical screeningNo resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
HepatotoxicityLiverStem / stalkRat (as animal)Short-term toxicityNo resolvable identifier

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

OutcomeEndpointTestTested organismMetabolic activationSource
Positivechromosome aberrationchromosome aberration assayHuman (as organism)No dataResolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Ananthi, R., Chandra, N., Santhiya, S. T., Ramesh, A. Genotoxic and antigenotoxic effects of Hemidesmus indicus R. Br. root extract in cultured lymphocytes. JOURNAL OF ETHNOPHARMACOLOGY, 2010, vol. 127, no. 2, p. 558-560. DOI
  2. Arseculeratne S N., Gunatilaka A A., Panabokke R G. Studies of medicinal plants of Sri Lanka. Part 14: Toxicity of some traditional medicinal herbs. Journal of ethnopharmacology, 1985, p. 323-335.
  3. Rekha, S., Parvathi, A. Evaluation of phytochemical constituents of the roots of licorice, Indian ginseng, Indian madder and Indian Sarsaparilla. International Journal of Pharma and Bio Sciences, 2012, vol. 3, no. 2, p. 357-362.
  4. Deepak, D., Srivastava, S., Khare, A. Pregnane glycosides from Hemidesmus indicus. PHYTOCHEMISTRY, 1997, vol. 44, no. 1, p. 145-151. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue